Clinically relevant subgroups in COPD and asthma

Eur Respir Rev June 1, 2015 vol. 24 no. 136 283-298

Alice M. Turner1,2⇑, 

Lilla Tamasi3, 

Florence Schleich4, 

Mehmet Hoxha5,

Ildiko Horvath3, 

Renaud Louis4 and 

Neil Barnes6

+Author Affiliations

1. ¹Clinical and Experimental Medicine, University of Birmingham, Queen Elizabeth Hospital Birmingham, Birmingham, UK
2. ²Dept of Respiratory Medicine, Birmingham Heartlands Hospital, Birmingham, UK
3. ³Dept of Pulmonology, Semmelweis University, Budapest, Hungary
4. ⁴Respiratory Medicine, CHU Sart-Tilman B35, Liege, Belgium
5. ⁵Service of Allergology and Clinical Immunology, UHC “Mother Teresa”, Tirana, Albania
6. ⁶GlaxoSmithKline, Stockley Park West, Uxbridge, UK

1. Alice M. Turner, Clinical and Experimental Medicine, University of Birmingham, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham, B15 2WB, UK. E-mail: a.m.wood@bham.ac.uk
2. 
   
3. Abstract

As knowledge of airways disease has grown, it has become apparent that neither chronic obstructive pulmonary disease (COPD) nor asthma is a simple, easily defined disease. In the past, treatment options for both diseases were limited; thus, there was less need to define subgroups. As treatment options have grown, so has our need to predict who will respond to new drugs. To date, identifying subgroups has been largely reported by detailed clinical characterisation or differences in pathobiology. These subgroups are commonly called “phenotypes”; however, the problem of defining what constitutes a phenotype, whether this should include comorbid diseases and how to handle changes over time has led to the term being used loosely.

Clinical asthma phenotyping: A trial for bridging gaps in asthma management

• Journal List
• World J Clin Pediatr
• v.4(2); 2015 May 8
• PMC4438436

World J Clin Pediatr. 2015 May 8; 4(2): 13–18.

Published online 2015 May 8. doi:  10.5409/wjcp.v4.i2.13

PMCID: PMC4438436

Magdy Mohamed Zedan, Wafaa Nabil Laimon, Amal Mohamed Osman, and Mohamed Magdy Zedan

Author information ► Article notes ► Copyright and License information ►

Abstract:

Asthma is a common disease affecting millions of people worldwide and exerting an enormous strain on health resources in many countries. Evidence is increasing that asthma is unlikely to be a single disease but rather a series of complex, overlapping individual diseases or phenotypes, each defined by its unique interaction between genetic and environmental factors.

Thresholds in chemical respiratory sensitisation

Toxicology

Volume 333, 3 July 2015, Pages 179–194

Stella A. Cochrane^a, , , 

Josje H.E. Arts^b, 

Colin Ehnes^c, 

Stuart Hindle^d, 

Heli M. Hollnagel^d, 

Alan Poole^e, 

Hidenori Suto^f, 

Ian Kimber^g

Abstract

There is a continuing interest in determining whether it is possible to identify thresholds for chemical allergy. Here allergic sensitisation of the respiratory tract by chemicals is considered in this context. This is an important occupational health problem, being associated with rhinitis and asthma, and in addition provides toxicologists and risk assessors with a number of challenges.

Masticatory Changes in Oral Breath Secondary to Allergic Rhinitis: Integrative Review

• Int Arch Otorhinolaryngol
• v.18(2); 2014 Apr
• PMC4297040

Luciana Ângelo Bezerra,1 Hilton Justino da Silva,2 Ana Carolina Cardoso de Melo,3 Klyvia Juliana Rocha de Moraes,4Renata Andrade da Cunha,1 Daniele Andrade da Cunha,2 and Décio Medeiros5

Author information ► Article notes ► Copyright and License information ►

Abstract

Introduction The III Brazilian Consensus on Rhinitis (2012) defines allergic rhinitis as a nasal mucosa inflammation, mediated by immunoglobulin E, after exposure to allergens.

Predictors of treatment with antibiotics and systemic corticosteroids for acute exacerbations of asthma and chronic obstructive pulmonary disease in primary care

Research article

Salwan Al-ani^1*, Mark Spigt¹², Johanna Laue¹ and Hasse Melbye¹

BMC Family Practice 2015, 16:40  doi:10.1186/s12875-015-0256-3

Abstract

Background

Antibiotic and oral corticosteroid prescribing rate in patients suffering from acute exacerbations of chronic obstructive pulmonary disease (COPD) or asthma in general practice are only sparsely described. Our aim was to identify predictors for such prescribing when results from CRP testing, spirometry, and pulse oximetry are available.

Lies, damned lies, and marketing: an editor’s lament

Vol 7, No 4 (April 2015) / Lies, damned lies, and marketing: an editor’s lament

Article Abstract

Authors: Lawrence Grouse

Abstract

Many of the articles published in the ICC COLUMN have emphasized the plight that respiratory patients around the world have in obtaining satisfactory access to appropriate medications and health care. Two main problems have been identified. The first involves the high costs that prevent many patients from obtaining care (1). The second involves the difficulty to determine whether or not new medications, diagnostic procedures, and treatments actually do benefit patient outcomes. This paper provides an editor’s perspective on how the marketing activities of proprietary organizations make it difficult to assess published clinical research that is intended to determine the value of treatments.

Whistles and wheezes: don't miss diseases

Arch Dis Child Educ Pract Ed 2015;100:132-143 doi:10.1136/archdischild-2013-304604

• Problem solving in clinical practice

1. J Cyriac, 
2. K Huxstep

+Author Affiliations

1. Department of Paediatrics, Broomfield Hospital, Chelmsford, UK

Abstract

Upper airway obstruction (UAO) in infants and children has a broad spectrum of presentations including benign self-resolving conditions, from mild croup, to critical life-threatening conditions which, though uncommon now, require prompt recognition and effective multidisciplinary collaborative management to achieve a good outcome. The aim of this article is to highlight the diagnostic and management difficulties in acute UAO in paediatric patients and encourage a problem-solving approach.

This Article

1. Full text
2. PDF
3. All Versions of this Article:

   1. archdischild-2013-304604v1
   2. 100/3/132 most recent

Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score

Research

Alain Didier^1*, Hans-Jørgen Malling², Margitta Worm³, Friedrich Horak⁴ and Gordon L Sussman⁵

Clinical and Translational Allergy 2015, 5:12  doi:10.1186/s13601-015-0057-8

Abstract

Background

The 300IR (index of reactivity) 5-grass pollen tablet has favorable short-term and sustained clinical efficacy in patients with grass pollen-induced allergic rhinoconjunctivitis (ARC). Here, we report maintenance of efficacy and safety over 2 years following treatment discontinuation.

European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars

Editorial

Carlo Agostini^1*, Giorgio Walter Canonica² and Enrico Maggi³

Clinical and Molecular Allergy 2015, 13:3  doi:10.1186/s12948-015-0010-3

The electronic version of this article is the complete one and can be found online at:http://www.clinicalmolecularallergy.com/content/13/1/3

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Viewing options

• Full text
• PDF(299KB)
•